Insulet Free Cash Flow 2010-2024 | PODD
Insulet annual/quarterly free cash flow history and growth rate from 2010 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
- Insulet free cash flow for the quarter ending December 31, 2024 was 305.40, a year-over-year.
- Insulet free cash flow for the twelve months ending December 31, 2024 was , a year-over-year.
- Insulet annual free cash flow for 2024 was $0.305B, a 335.66% increase from 2023.
- Insulet annual free cash flow for 2023 was $0.07B, a 1897.44% decline from 2022.
- Insulet annual free cash flow for 2022 was $-0.004B, a 97.83% decline from 2021.
| Insulet Annual Free Cash Flow | |
|---|---|
| 2024 | 305.40 |
| 2023 | 70.10 |
| 2022 | -3.90 |
| 2021 | -180.00 |
| 2020 | -45.00 |
| 2019 | -65.30 |
| 2018 | -121.50 |
| 2017 | -32.50 |
| 2016 | -6.20 |
| 2015 | -23.16 |
| 2014 | -2.57 |
| 2013 | -3.96 |
| 2012 | -40.05 |
| 2011 | -36.57 |
| 2010 | -42.17 |
| 2009 | -52.46 |
| Insulet Quarterly Free Cash Flow | |
|---|---|
| 2024-12-31 | 305.40 |
| 2024-09-30 | 211.30 |
| 2024-06-30 | 139.50 |
| 2024-03-31 | 65.50 |
| 2023-12-31 | 70.10 |
| 2023-09-30 | 54.20 |
| 2023-06-30 | 18.30 |
| 2023-03-31 | -10.00 |
| 2022-12-31 | -3.90 |
| 2022-09-30 | 9.80 |
| 2022-06-30 | -15.80 |
| 2022-03-31 | -26.50 |
| 2021-12-31 | -180.00 |
| 2021-09-30 | -122.70 |
| 2021-06-30 | -69.60 |
| 2021-03-31 | -68.00 |
| 2020-12-31 | -45.00 |
| 2020-09-30 | -11.20 |
| 2020-06-30 | -28.90 |
| 2020-03-31 | -30.50 |
| 2019-12-31 | -65.30 |
| 2019-09-30 | -63.10 |
| 2019-06-30 | -71.50 |
| 2019-03-31 | -37.90 |
| 2018-12-31 | -121.50 |
| 2018-09-30 | -119.40 |
| 2018-06-30 | -98.13 |
| 2018-03-31 | -39.64 |
| 2017-12-31 | -32.50 |
| 2017-09-30 | -28.41 |
| 2017-06-30 | -42.94 |
| 2017-03-31 | -47.51 |
| 2016-12-31 | -6.20 |
| 2016-09-30 | -23.36 |
| 2016-06-30 | -12.74 |
| 2016-03-31 | -13.68 |
| 2015-12-31 | -23.16 |
| 2015-09-30 | -1.08 |
| 2015-06-30 | -7.30 |
| 2015-03-31 | -7.83 |
| 2014-12-31 | -2.57 |
| 2014-09-30 | -4.54 |
| 2014-06-30 | -6.25 |
| 2014-03-31 | -3.17 |
| 2013-12-31 | -3.96 |
| 2013-09-30 | 2.35 |
| 2013-06-30 | 0.48 |
| 2013-03-31 | -2.27 |
| 2012-12-31 | -40.05 |
| 2012-09-30 | -32.40 |
| 2012-06-30 | -24.27 |
| 2012-03-31 | -10.60 |
| 2011-12-31 | -36.57 |
| 2011-09-30 | -26.62 |
| 2011-06-30 | -22.51 |
| 2011-03-31 | -10.76 |
| 2010-12-31 | -42.17 |
| 2010-09-30 | -31.55 |
| 2010-06-30 | -17.04 |
| 2010-03-31 | -10.27 |
| 2009-12-31 | -52.46 |
| 2009-09-30 | -41.43 |
| 2009-06-30 | -29.22 |
| 2009-03-31 | -13.14 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $17.717B | $2.072B |
| Insulet Corporation is a leading developer, manufacturer and marketer of the Omnipod Insulin Management System. The system is equipped with a self-adhesive, small and lightweight disposable tubeless Omnipod device along with the wireless and handheld Personal Diabetes Manager (PDM). The Omnipod System is an innovative, discreet and easy-to-use continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System consists of Omnipod Insulin Management System ('Omnipod') and the Omnipod DASH Insulin Management System - Insulet's next generation digital mobile Omnipod platform. Insulet has tied up with pharmaceutical and biotechnological companies using customized form of the Omnipod System to deliver a drug at a certain administered volume and over a specified period of time. Insulet has partnered with pharmaceutical and biotechnology companies to tailor the Omnipod System technology platform for the delivery of subcutaneous drugs across other therapeutic areas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $226.763B | 27.35 |
| Boston Scientific (BSX) | United States | $152.152B | 38.10 |
| Stryker (SYK) | United States | $142.721B | 30.67 |
| EssilorLuxottica (ESLOY) | France | $133.556B | 0.00 |
| Medtronic (MDT) | Ireland | $108.708B | 15.87 |
| Lonza Group Ag (LZAGY) | Switzerland | $51.613B | 0.00 |
| Haleon (HLN) | United Kingdom | $45.796B | 26.03 |
| ResMed (RMD) | United States | $34.691B | 26.06 |
| GE HealthCare Technologies (GEHC) | United States | $32.200B | 15.29 |
| Agilent Technologies (A) | United States | $30.677B | 20.26 |
| Terumo (TRUMY) | Japan | $28.397B | 0.00 |
| Koninklijke Philips (PHG) | Netherlands | $23.827B | 17.01 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.388B | 12.88 |
| Baxter (BAX) | United States | $15.988B | 11.50 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.272B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $7.609B | 0.00 |
| Demant (WILYY) | Denmark | $7.600B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $7.145B | 17.57 |
| Bio-Rad Laboratories (BIO) | United States | $6.837B | 23.67 |
| Prestige Consumer Healthcare (PBH) | United States | $4.024B | 19.20 |
| Perrigo (PRGO) | Ireland | $3.510B | 10.05 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| ICU Medical (ICUI) | United States | $3.362B | 28.64 |
| Haemonetics (HAE) | United States | $3.166B | 14.90 |
| Envista Holdings (NVST) | United States | $2.725B | 22.03 |
| GN Store Nord (GNNDY) | Denmark | $2.260B | 18.72 |
| LeMaitre Vascular (LMAT) | United States | $2.050B | 46.77 |
| QuidelOrtho (QDEL) | United States | $1.875B | 15.70 |
| AtriCure (ATRC) | United States | $1.480B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.401B | 22.00 |
| Kestra Medical Technologies (KMTS) | United States | $1.235B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.148B | 11.05 |
| BioLife Solutions (BLFS) | United States | $1.145B | 0.00 |
| Neogen (NEOG) | United States | $1.096B | 14.03 |
| InMode (INMD) | Israel | $0.981B | 8.98 |
| Phibro Animal Health (PAHC) | United States | $0.754B | 11.56 |
| Evolus (EOLS) | United States | $0.735B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.713B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.580B | 0.00 |
| CeriBell (CBLL) | United States | $0.577B | 0.00 |
| Owens & Minor (OMI) | United States | $0.545B | 4.64 |
| Valneva SE (VALN) | France | $0.531B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.514B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.488B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.479B | 0.00 |
| Omeros (OMER) | United States | $0.427B | 0.00 |
| Surmodics (SRDX) | United States | $0.400B | 0.00 |
| SNDL (SNDL) | Canada | $0.392B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.357B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.343B | 14.86 |
| Verano Holdings (VRNOF) | United States | $0.323B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.284B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.279B | 25.25 |
| Aurora Cannabis (ACB) | Canada | $0.261B | 46.40 |
| Canopy Growth (CGC) | Canada | $0.254B | 0.00 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| ZimVie (ZIMV) | United States | $0.252B | 15.10 |
| OraSure Technologies (OSUR) | United States | $0.232B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.231B | 0.00 |
| Quanterix (QTRX) | United States | $0.223B | 0.00 |
| High Tide (HITI) | Canada | $0.195B | 0.00 |
| Biote (BTMD) | United States | $0.182B | 4.16 |
| Utah Medical Products (UTMD) | United States | $0.170B | 13.69 |
| TriSalus Life Sciences (TLSI) | United States | $0.166B | 0.00 |
| Brainsway (BWAY) | Israel | $0.164B | 51.00 |
| Organigram Global (OGI) | Canada | $0.146B | 0.00 |
| Jin Medical (ZJYL) | China | $0.142B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.142B | 17.46 |
| TerrAscend (TSNDF) | Canada | $0.128B | 0.00 |
| Agape ATP (ATPC) | $0.115B | 0.00 | |
| Exagen (XGN) | United States | $0.112B | 0.00 |
| MacroGenics (MGNX) | United States | $0.109B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.095B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.093B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.082B | 0.00 |
| Veru (VERU) | United States | $0.079B | 0.00 |
| Fonar (FONR) | United States | $0.078B | 10.91 |
| InterCure (INCR) | Israel | $0.072B | 0.00 |
| United Health Products (UEEC) | United States | $0.065B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.063B | 0.00 |
| Zynex (ZYXI) | United States | $0.050B | 0.00 |
| ImmuCell (ICCC) | United States | $0.049B | 0.00 |
| Modular Medical (MODD) | United States | $0.044B | 0.00 |
| Apyx Medical (APYX) | United States | $0.039B | 0.00 |
| Safety Shot (SHOT) | United States | $0.039B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.037B | 54.00 |
| United-Guardian (UG) | United States | $0.036B | 11.14 |
| Nephros (NEPH) | United States | $0.021B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Flora Growth (FLGC) | United States | $0.011B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.009B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.007B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.004B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |